Advanced Filters
noise

Biejing, China Clinical Trials

A listing of Biejing, China clinical trials actively recruiting patients volunteers.

Found 2,216 clinical trials

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

18 years of age All Phase 3

Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

18 years of age All Phase 1

Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

This is a Phase II, open-label study designed to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of AL01211 in male subjects with classic Fabry disease who have never received any treatment (eg. ERT or chaperone therapy). Eligible subjects will receive 182 days (26 weeks) of study treatment as …

18 - 60 years of age Male Phase 2
J Jie Yu

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159 monotherapy in pediatric patients with refractory/recurrent Langerhans cell histiocytosis (LCH).

2 - 16 years of age All Phase 2
Y Yuqin Song, Doctor

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

18 - 80 years of age All Phase 1
D Daihong Liu

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.

14 - 75 years of age All Phase 1
J Junjie Wang, M.D.

3DPCT Combined With CT Guided RISI in the Treatment of Thoracic Malignant Tumors

The main technical difficulties in radioactive iodine-125 seed implantation (RISI) lie in the complexity of operation and the control of operation quality. The current data shows that under the combined guidance of 3D-printing template and CT, the accuracy of RISI has been significantly improved, and the actual target dose could …

18 - 80 years of age All Phase N/A
D Daihong Liu

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) or EBV infection

1 - 60 years of age All Phase 1
F Fu-Sheng Wang, MD

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.

18 - 65 years of age All Phase 1/2
C Cuicui Cong

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory …

18 years of age All Phase 2

Simplify language using AI